A new study says common human typing errors can trip up artificial intelligence (AI) programs designed to aid health care ...

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Novo Nordisk (NVO) has partnered with WeightWatchers (OTC:WGHTQ) to sell its obesity drug Wegovy days after exiting a similar ...

Including the $20 serum Drew Barrymore likes to "douse" herself with and the $17 lotion Julia Roberts uses on her elbows, ...

Investing.com -- LifeMD Inc (NASDAQ: LFMD) stock rose 4.3% following Novo Nordisk’s (NYSE: NVO) announcement that it will continue its collaboration with the telehealth provider to offer patients ...

Investing.com -- Hims & Hers Health (NYSE: HIMS) has named Dheerja Kaur as its first-ever Chief Product Officer, according to an announcement from CEO Andrew Dudum.

Novo Nordisk says the decision was made based on “Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” ...

The heavy selling pressure might have exhausted for Hims & Hers Health (HIMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...

AI trade rebounds as Nvidia leads generative AI surge. Explore key market moves, tech earnings insights, and ETF performance.

Novo Nordisk (NYSE: NVO) severed its partnership with Hims & Hers (NYSE: HIMS), arguing that the company breached the ...